Burning questions about FDA's response to abortion pill decisions; how big of a pay bump do hospitals need from Medicare next year?

STAT spoke with regulatory and legal experts about what comes next for the FDA and drugmakers after conflicting abortion pill rulings.

April 11, 2023 Check out STAT+

Sponsored By

Paul Ratje/The Washington Post 6 burning questions about how the FDA will handle conflicting abortion pill decisions STAT spoke with regulatory and legal experts about what comes next for the FDA and drugmakers after conflicting abortion pill rulings. By Sarah Owermohle and Ed Silverman EPA proposes limits on carcinogenic gas used to sterilize medical devices The EPA has proposed new limits on the use of a carcinogenic gas called ethylene oxide, which is used to sterilize medical devices. By Brittany Trang and Lizzy Lawrence STAT+ | Just how big of a pay bump do hospitals need from Medicare next year? The federal government is proposing to give hospitals a 2.8% raise in their Medicare payments next year. Hospitals want more. By Bob Herman Adam Fagen STAT+ | 'It was my call': Stanford president defends decision not to correct key paper in misconduct investigation "It was my call to conduct additional follow-up experiments rather than to correct or retract the 2009 study," Tessier-Lavigne told STAT. By Jonathan Wosen Where is PhRMA in the mifepristone debate? A judge's decision to suspend FDA approval of an abortion pill could impact pharma, but its lobbying association is staying on the sidelines. By Rachel Cohrs STAT+ | Oracle's Cerner Enviza launches a new effort to use AI to study asthma drug safety Oracle's Cerner Enviza will work with John Snow Labs on AI tools to search patient records for side effects from the asthma drug montelukast. By Brittany Trang Adobe STAT+ | A biotech upstart takes on cancer by crowdsourcing the immune system's natural killers The Bay Area biotech believes it can harness the diversity of the immune system to treat a range of deadly cancers. By Jonathan Wosen Opinion: The mifepristone debacle is just the latest blow in an ongoing assault on the FDA's authority The mifepristone ruling undermines the FDA's prerogative to approve or reject new drug applications, creating massive uncertainty. By Cartier Esham and John Murphy

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser